These are extraordinary news. Statistically speak

These are extraordinary news. Statistically speaking, we have today probed that we are a bona fide Oncology company. Period.

My read from communication (it was crafted a bit awkwardly for us investors, but from the trial progression perspective it makes sense) :

Patient #1: New data from the first patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of circulating tumor cells (CTC) with leronlimab in combination with carboplatin at 16 weeks of treatment

Patient #3: New data from the second patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of CTC with leronlimab in combination with carboplatin after two weeks of treatment. This patient also showed a 70% reduction in EMT cells after just two weeks of treatment.

Patient#4: Initial data from the third patient in the mTNBC trial indicated the CTC dropped to zero after two weeks of treatment with leronlimab.

Patient #2 (M-i-l) : New findings from the patient enrolled through an emergency investigational new drug (IND) with stage 4 HER2+ MBC that has metastasized to the liver, lung and brain, demonstrate no new metastasis in the brain after treatment with leronlimab as the only product for the metastasis to her brain. Prior to enrolling in the trial, the patient had 18 identifiable tumor spots in the brain. Today, following two months of weekly 700 mg doses of leronlimab, there are only three identifiable lesions, as seen in an MRI. This patient’s radiologist cancelled the suggested new round of radiation due to results that he believes is due only to leronlimab.